Both lawsuits state claims based on specific time periods, and there's no overlap on those, Delaware Superior Court Judge Paul R. Wallace noted. Additionally, with a new board of directors put in place in spring 2017, the two cases don't name the same individual defendants. Credit: Bill Gallery/Adobe Stock
The fact that a single drug's development is at the center of multiple lawsuits against Gilead Sciences subsidiary Immunomedics Inc. doesn't mean a D&O insurance provider can't provide coverage in each case, Delaware Superior Court Judge Paul R. Wallace decided on March 18, 2024.
Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader
Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
- Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Ellen Bardash
Ellen Bardash is ALM's reporter covering corporate litigation for Law.com and Delaware Business Court Insider. She can be contacted by emailing [email protected] or following @ellenbardash.bsky.social on Bluesky.
